Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Larimar Secures PRIME Designation In EU For Neurological Disease Drug

Support Scheme Accepts Potential Treatment For Friedreich’s Ataxia

Executive Summary

The European Medicines Agency has accepted Larimar’s potential treatment for Friedreich’s ataxia onto its PRIME scheme for helping to get medicines for unmet medical needs to patients faster.

You may also be interested in...



Clinical Hold Halts Larimar’s Friedrich’s Ataxia Candidate And Financing

Looking to develop the first drug therapy for FA, Larimar gets US FDA hold due to deaths in non-human primate study. This alters clinical development timelines and fundraising plans for the firm.

Winners And Losers: A Deep-Dive Into The EMA’s PRIME Scheme

Nine of the 70 medicines for unmet medical needs that have to date won a place on the European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more approvals are expected soon. Meanwhile, most applications for a "priority medicine" designation are still missing the mark.

Ophthalmic Bevacizumab Reaches Critical Review Stage In EU

The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel